Esomeprazole Magnesium
Product Images NDC 68071-2919

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 68071-2919). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2919 9)

Packaging label for Esomeprazole Magnesium 40mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label shows a count of 90 capsules, manufactured by Graviti Pharmaceuticals Pvt. Ltd., Telangana, India, and packaged by NuCare Pharmaceuticals, Inc., Orange, CA. It includes NDC 68071-2919-9 and states the capsules contain 44.50mg of Esomeprazole Magnesium Trihydrate equivalent to 40mg Esomeprazole. Storage instructions advise controlled temperature 68-77°F and warnings to keep out of reach of children.*

FDA Label Image

Image (B201c94c 128a 4ae1 86a1 057c4c895839 01)

Chemical structure of esomeprazole magnesium. The diagram illustrates the molecular structure including aromatic rings, nitrogen, oxygen, sulfur atoms, magnesium ion complexed with three water molecules.*

FDA Label Image

Figure 2: Maintenance Of Healing Rates By Month (study 177) (B201c94c 128a 4ae1 86a1 057c4c895839 02)

A line graph depicting the percentage maintained over a six-month period for Esomeprazole Magnesium Delayed-Release Capsules 40 mg compared to placebo. The y-axis represents percent maintained, ranging from 0 to 100%, and the x-axis represents months from 0 to 6. Four lines show different group data, including three Esomeprazole Magnesium delayed-release capsule groups and one placebo group, with the Esomeprazole groups generally maintaining higher percentages than the placebo over time.*

FDA Label Image

Figure 3: Maintenance Of Healing Rates By Month (study 178) (B201c94c 128a 4ae1 86a1 057c4c895839 03)

A line graph depicting the percentage of subjects maintaining a condition over six months for Esomeprazole Magnesium Delayed-Release Capsules at strengths of 40 mg, 20 mg, 10 mg, and a placebo group. The x-axis shows the months (1 through 6), and the y-axis indicates the percent maintained (0 to 100%). The 40 mg group maintains the highest percentage, followed by 20 mg, 10 mg, and placebo with the lowest maintenance over time.*

FDA Label Image

Figure 4: Percent Of Patients Symptom-free Of Heartburn By Day (study 225) Figure (B201c94c 128a 4ae1 86a1 057c4c895839 04)

A line graph comparing the percent of patients symptom-free over 28 days among three groups receiving Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo. The x-axis represents diary days from 0 to 28, and the y-axis shows the percentage of symptom-free patients ranging from 0 to 100.*

FDA Label Image

Image (B201c94c 128a 4ae1 86a1 057c4c895839 05)

A line graph depicting the percent of patients symptom-free over 28 diary days. It compares Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo groups. The y-axis represents percent symptom-free patients, and the x-axis represents diary days, highlighting trends in symptom relief over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.